Literature DB >> 25012524

Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015.

Robert J van Soest1, Ronald de Wit2, Wytske M van Weerden3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25012524     DOI： 10.1016/j.eururo.2014.06.038

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  3 in total

Review 1.  Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.

Authors:  K Fizazi; C Jenkins; I F Tannock
Journal:  Ann Oncol       Date:  2015-05-22       Impact factor: 32.976

2.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Authors:  S Gillessen; A Omlin; G Attard; J S de Bono; E Efstathiou; K Fizazi; S Halabi; P S Nelson; O Sartor; M R Smith; H R Soule; H Akaza; T M Beer; H Beltran; A M Chinnaiyan; G Daugaard; I D Davis; M De Santis; C G Drake; R A Eeles; S Fanti; M E Gleave; A Heidenreich; M Hussain; N D James; F E Lecouvet; C J Logothetis; K Mastris; S Nilsson; W K Oh; D Olmos; A R Padhani; C Parker; M A Rubin; J A Schalken; H I Scher; A Sella; N D Shore; E J Small; C N Sternberg; H Suzuki; C J Sweeney; I F Tannock; B Tombal
Journal:  Ann Oncol       Date:  2015-06-03       Impact factor: 32.976

Review 3.  Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance.

Authors:  Styliani Karanika; Theodoros Karantanos; Jianhua Yin; Likun Li; Timothy C Thompson
Journal:  Asian J Urol       Date:  2015-04-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.